Last Updated: November 13, 2026

Shionogi Company Profile

« Back to Dashboard


What is the competitive landscape for SHIONOGI

SHIONOGI has eleven approved drugs.

There are eighteen US patents protecting SHIONOGI drugs.

Summary for Shionogi
US Patents:18
Tradenames:11
Ingredients:9
NDAs:11
Patent Litigation for Shionogi: See patent lawsuits for Shionogi

Drugs and US Patents for Shionogi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi XOCOVA ensitrelvir TABLET;ORAL 220442-001 May 29, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 DISCN No No ⤷  Start Trial ⤷  Start Trial
Shionogi UROPLUS DS sulfamethoxazole; trimethoprim TABLET;ORAL 071816-001 Sep 28, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial
Shionogi RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes 12,599,586 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Shionogi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 6,793,931 ⤷  Start Trial
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 5,464,632 ⤷  Start Trial
Shionogi DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-002 Oct 5, 2010 5,317,016 ⤷  Start Trial
Shionogi DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-001 Oct 12, 2007 8,247,402 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SHIONOGI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 2011-10-11
➤ Subscribe Lotion 5% ➤ Subscribe 2016-04-11

Supplementary Protection Certificates for Shionogi Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2960244 CR 2020 00049 Denmark ⤷  Start Trial PRODUCT NAME: CEFIDEROCOL, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200424
2960244 132020000000136 Italy ⤷  Start Trial PRODUCT NAME: CEFIDEROCOL, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE O SOLVATO(FETCROJA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1434, 20200424
0306228 SPC/GB01/002 United Kingdom ⤷  Start Trial PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
1307486 12C0041 France ⤷  Start Trial PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.